Targovax enters collaboration with Leidos to add checkpoint inhibitor functionality to ONCOS viruses
· Targovax and Leidos will jointly explore the potential of combining their ONCOS and Microtide[TM] technology platforms · ONCOS will be used for intra-tumoral delivery of Microtide™ checkpoint inhibitor peptides Oslo, Norway 4 June 2020 – Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that it has entered into a collaboration agreement with the Explorations in Global Health (ExGloH) Division of Leidos to evaluate the potential of using ONCOS oncolytic adenoviruses as a vector to